AI Article Synopsis
- The study examines the controversial link between proton pump inhibitors (PPIs) and dementia by analyzing adverse event reports from the FDA database spanning 2004 to 2023.
- It found a significant association between the use of PPIs and dementia, particularly with common PPIs like omeprazole, pantoprazole, and esomeprazole, using specific statistical methods to minimize bias.
- The authors conclude that while there is a noted connection between dementia and PPI use, more thorough and high-quality studies are required for further understanding.
Article Abstract
Objective: The association between proton pump inhibitor (PPI) and dementia was controversial. The aim of the current study was to perform an updated pharmacovigilance analysis of the association between dementia event and PPI treatment after minimizing competition bias.
Methods: We gathered cases reported with PPI treatment based on the United States Food and Drug Administration Adverse Event Reporting System database from 2004 to 2023. We employed disproportionality algorithms, including reporting odds ratio (ROR) and the information component (IC), to detect the association between dementia event and PPI. We investigated the affection of event competition bias on the current disproportionality signal detection.
Results: We finally included a total of 776,191 PPI cases, and 1813 cases in the dementia group. Analyzing primary suspect PPIs, we detected a significant association between dementia and PPI (ROR = 1.38, 95%CI 1.22 to 1.56; IC = 0.46, 95%CI 0.04 to 0.86). After excluding the PPI case with renal injury events, the strength of the dementia signal increased. Omeprazole (589 cases), pantoprazole (514 cases), and esomeprazole (386 cases) were the top three PPI reported with dementia events.
Conclusion: The current pharmacovigilance study identified a significant association between dementia and PPIs, except vonoprazan and tegoprazan, especially taking competition bias into account. Further high-quality prospective study still needed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/14740338.2024.2387314 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Comparison of the amyloid plaque proteome in Down syndrome, early-onset Alzheimer's disease, and late-onset Alzheimer's disease.
Acta Neuropathol
January 2025
Department of Neurology, NYU Grossman School of Medicine, New York, NY, USA.
Down syndrome (DS) is strongly associated with Alzheimer's disease (AD) due to APP overexpression, exhibiting Amyloid-β (Aβ) and Tau pathology similar to early-onset (EOAD) and late-onset AD (LOAD). We evaluated the Aβ plaque proteome of DS, EOAD, and LOAD using unbiased localized proteomics on post-mortem paraffin-embedded tissues from four cohorts (n = 20/group): DS (59.8 ± 4.
View Article and Find Full Text PDFLiving in Historically Redlined Neighborhoods and the Cognitive Function of Black and White Adults.
J Aging Health
January 2025
School of Public Policy & Maryland Population Research Center, University of Maryland, College Park, MD, USA.
Objectives: We determined if living in historically redlined neighborhoods was associated with level and change in cognitive functioning and if this association differed for Black and White older adults.
Methods: We linked the Health and Retirement Study 1998-2018 data to redlining scores from the Historic Redlining Indicator data. Our sample included adults aged 50 years and older (24,230 respondents, 129,618 person-period observations).
Prevalence and associated factors of healthy aging among community-dwelling older adults in Lishui city, China: a cross-sectional study.
BMC Public Health
January 2025
Department of Nursing, School of Medicine, Lishui University, No. 1 Xueyuan Road, Lishui City, Zhejiang Province, 323000, China.
Background: Identifying the level of healthy aging and exploring its associated factors are prerequisites in the planning of effective measures among the elderly population. Thus, this study aimed to investigate the prevalence of healthy aging and determine its associated factors among community-dwelling older adults from mountain areas in Lishui, China.
Methods: A multicenter cross-sectional survey was conducted.
Somatic CAG repeat expansion in blood associates with biomarkers of neurodegeneration in Huntington's disease decades before clinical motor diagnosis.
Nat Med
January 2025
Huntington's Disease Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK.
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease with the age at which characteristic symptoms manifest strongly influenced by inherited HTT CAG length. Somatic CAG expansion occurs throughout life and understanding the impact of somatic expansion on neurodegeneration is key to developing therapeutic targets. In 57 HD gene expanded (HDGE) individuals, ~23 years before their predicted clinical motor diagnosis, no significant decline in clinical, cognitive or neuropsychiatric function was observed over 4.
View Article and Find Full Text PDFAssociation between herpes simplex virus infection and Alzheimer's disease biomarkers: analysis within the MAPT trial.
Sci Rep
January 2025
INSERM, Bergonié Institute, BPH, U1219, CIC-P 1401, University of Bordeaux, Bordeaux, France.
In vitro and animal studies have suggested that inoculation with herpes simplex virus 1 (HSV-1) can lead to amyloid deposits, hyperphosphorylation of tau, and/or neuronal loss. Here, we studied the association between HSV-1 and Alzheimer's disease biomarkers in humans. Our sample included 182 participants at risk of cognitive decline from the Multidomain Alzheimer Preventive Trial who had HSV-1 plasma serology and an amyloid PET scan.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!